<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185025</url>
  </required_header>
  <id_info>
    <org_study_id>v2.0</org_study_id>
    <nct_id>NCT04185025</nct_id>
  </id_info>
  <brief_title>Compare the Skin Barrier Repair Function of Two Ceramide Containing Moisturizers</brief_title>
  <official_title>Compare the Skin Barrier Repair Function of Two Ceramide Containing Moisturizers: A Double-blind, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the improvement of CeraVe moisturising lotion on the cuticle
      moisture of dry skin and barrier repair function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-assessment from patients</measure>
    <time_frame>17 days</time_frame>
    <description>The patients fill out questionnaires and score erythema, desquamation, dryness, itching, and cleft palate on both sides of the calves (0 = none, 1 = light, 2 = medium, 3 = severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The loss of transdermal water</measure>
    <time_frame>0 day, 1 day, 7 days, 14 days, 17 days</time_frame>
    <description>The percutaneous water loss value of the test site is measured continuously in an open chamber with Tewameter (TM300, Courage and Khazaka, Germany), and the measurement is performed 3 times continuously. The average value is taken after the value is stable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cuticle moisture</measure>
    <time_frame>0 day, 1 day, 7 days, 14 days, 17 days</time_frame>
    <description>The water content in the stratum corneum of the test site is measured 5 times with Corneometer (CM825, Course and Khazaka, Germany) and the average value is taken.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>CeraVe Moisturising Lotion</condition>
  <arm_group>
    <arm_group_label>CeraVe Moisturising Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Half Mu ceramide body milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceramides</intervention_name>
    <description>On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the &quot;Product Use Procedures&quot;, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.</description>
    <arm_group_label>CeraVe Moisturising Lotion</arm_group_label>
    <arm_group_label>Half Mu ceramide body milk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those who volunteer to participate in the trial, sign the informed consent, be able to
             cooperate with follow-up observation, and conduct the trial according to the guidance
             of the doctor.

          -  Dry skin subjects with symmetrical distribution of forearm flexion diagnosed by a
             doctor.

          -  Those who are 30-80 years old, male or female.

          -  Those with good compliance who can not use other external drugs during the entire
             observation period.

        Exclusion Criteria:

          -  Those who do not sign the informed consent.

          -  Those with the history of allergies to test product and control product ingredients.

          -  Those who received or are receiving medical or physical therapy for any skin or
             systemic disease recently (â‰¤3 months)

          -  Those who have a large amount of exudation in the acute phase or who are infected at
             the test site.

          -  Female subjects who are preparing for pregnancy, pregnancy, lactation, or within six
             months after delivery.

          -  Those who participate in clinical trials of other moisturizing products or emollients.

          -  Those who are taking other oral medicines that affect the skin condition.

          -  Those who the investigator considers unsuitable for other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Wu</last_name>
      <phone>+86-13910978643</phone>
      <email>amy60436@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Yan Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

